Working Group on New TB Drugs Launches Strategic Plan 2011-2015

Click here to access publication.

The WGND Strategic Plan 2011-2015 is an update of the “New Drugs” section of the Global Plan to Stop TB: 2011-2015. It describes the progress, gaps, and vision of the WGND and the TB drug development field as a whole. Since its inception, the WGND has served as a venue for interaction among partners working in all stages of TB drug research and development, to increase efficiencies and decrease risk for the process as a whole. One of the lessons learned since the introduction of the existing anti-TB drugs is that continued multi-year worldwide commitment, research and vigilance to ensure a consistent pipeline of new antimicrobials will be required to eradicate TB in the 21st century. Thus, there is a need to sustain the critical collaborations between public and private partners to build the current portfolio, which have leveraged the scientific and clinical knowledge of industry, the public health sector, and world-wide academic laboratories. With its diverse membership, including representatives of all these constituencies, as well as regulators, representatives of affected communities and those in a position to provide funding and support, the WGND remains a unique mechanism for ensuring a consistent pipeline of drug candidates.

Click here to download the WGND Strategic Plan 2011-2015.

More News
17 Sep 2019
Earlier this month, the NIH announced two new Funding Opportunity Annoucnements (FOAs) on the topic of Myeloid-Derived Suppressor Cells (MDSC) as potential therapeutic targets in TB/HIV co-infected patients. The purpose of these FOAs is to invite applications for support of innovative clinical,...
14 Aug 2019
FDA released the following press release on Wednesday, August 14th: The U.S. Food and Drug Administration today approved Pretomanid Tablets in combination with bedaquiline and linezolid for the treatment of a specific type of highly treatment-resistant tuberculosis (TB) of the lungs. “The threat of...
27 Jun 2019
-- Globe Newswire reported on June 20th -- Spero Therapeutics, Inc. , a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing treatments in high unmet need areas involving multi-drug resistant (MDR) bacterial infections and rare diseases, today...